Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05205265
Other study ID # CIP-A-21-0001
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date May 10, 2022
Est. completion date December 2023

Study information

Verified date May 2024
Source NXT Biomedical
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical investigation is a prospective, multicenter, non-randomized, open-label, Early Feasibility Study to evaluate the safety, performance, and initial clinical efficacy of the Rivet PVS therapy in patients with symptomatic pulmonary hypertension.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 2023
Est. primary completion date December 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Select Inclusion Criteria: - Age = 18 years - Prior diagnosis of Group 2 PH due to HFpEF, with the following resting hemodynamic criteria confirmed in the past year by right heart catheterization a. mPAP = 25 mmHg at rest or mPAP/CO slope > 3 mmHg/L/min during incremental exercise - Confirmation of the following hemodynamic criteria during supine exercise a. PCWP = 25 mmHg, or PCWP/CO slope > 2 mmHg/L/min - Chronic symptomatic heart failure documented by the following: 1. NYHA HF Class II with history > II, or Class III, or ambulatory Class IV 2. = 1 HF hospitalization, or healthcare facility with IV diuretics or intensification of oral diuresis for HF within 12 months, or NT-pro BNP value > 400 pg/mL in normal sinus rhythm or > 750 pg/mL in atrial fibrillation in past 6 months - Ongoing stable guideline directed medical therapy (GDMT) for HF and medically optimized per treating HF physician according to current ACCF/AHA guidelines that is expected to be maintained without change for 6 months (excluding diuretic dosage changes for HF optimization within 90 days of the Index Procedure) - 6MWD = 150 m Select Exclusion Criteria: - Any therapeutic intracardiac intervention within the last 30 days - PH Group 1, 3, 4 or 5 - Mean RAP >12 mmHg by RHC at rest on room air - Right ventricular dysfunction, defined as one or more of the following 1. Greater than moderate RV dysfunction as assessed by TTE and/or MRI 2. RV FAC < 35% 3. TAPSE < 14 mm via TTE 4. RV size severely enlarged compared to LV size as estimated by TTE and/or MRI - Severe tricuspid valve regurgitation - Peak systolic pulmonary arterial pressure > 80 mmHg by RHC at rest while awake - Mean pulmonary arterial pressure > 50 mmHg by RHC at rest while awake - PVR > 6 Wood units at rest while awake on room air or exercise PVR > 2 Wood Units - Left ventricular ejection fraction < 50% - Severe heart failure, defined as one or more of the following: 1. ACC/AHA/ESC Stage D heart failure, non-ambulatory NYHA Class IV HF 2. If BMI < 30, Cardiac Index < 2.0 L/min/m2 3. If BMI = 30, Cardiac Index < 1.8 L/min/m2 4. Requires continuous intravenous inotropic infusion 5. Requires mechanical circulatory support 6. Currently on the cardiac transplant waiting list - Chronic renal dysfunction defined as one or more of the following: 1. Currently requiring dialysis; OR 2. eGFR < 35 mL/min/1.73 m2 by the CKD-Epi equation - Chronic pulmonary disease defined as one or more of the following: 1. Requires continuous home oxygen therapy 2. Recent hospitalization for exacerbation within 12 months prior to screening 3. FEV1 < 50% predicted

Study Design


Intervention

Device:
Rivet Shunt
The Rivet Shunt device will be implanted via a percutaneous, transcatheter approach

Locations

Country Name City State
United States Massachusetts General Hospital Boston Massachusetts
United States UVA Cardiology Research Charlottesville Virginia
United States Mayo Clinic Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
NXT Biomedical

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of Major Adverse Events Composite of major adverse cardiac, cerebrovascular, or renal events (MACCRE) and re-intervention for study device related complications at implantation procedure (Day 0) and up to 1-month post-procedure (Day 30) 1 month
Primary Rate of Technical Success of the Rivet Shunt Implantation Procedure Study device is implanted as intended and confirmation of a patent pulmonary-to-venous shunt between the RPA and SVC by qualitative assessment via angiography and/or echocardiography at implantation procedure. At time of procedure
Secondary Adverse Events through 12 months Composite of MACCRE and re-intervention for study device related complications (as described above), progression of PH and/or HF disease, and all-cause mortality to 12 months post-procedure 12 months
Secondary Change in Hemodynamics at 12 months - PCWP Change in exercise pulmonary capillary wedge pressure (PCWP) from baseline 12 Months
Secondary Change in Kansas City Cardiomyopathy Questionnaire Change in KCCQ score between baseline and 12 months. 12 months
Secondary Change in RV Chamber Size at 12 months - Diameter Change in RV Chamber Size (Diameter) assessed by a core lab between baseline and 12 months 12 months
Secondary Change in Hemodynamics at 12 months - mPAP/CO Slope Change in exercise mPAP/CO Slope (mean pulmonary artery pressure/cardiac output slope) from baseline 12 months
Secondary Change in RV function at 12 months - RV Fractional Area Change (FAC) Change in RV FAC assessed by a core lab between baseline and 12 months 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy